aTyr Pharma cuts workforce about 60% and narrows Q2 2026 net loss to $10.3 million
aTyr Pharma reported a second quarter 2026 net loss of $10.3 million, or $0.11 per share, down from $19.5 million, or $0.22 per share, a year earlier, and announced a workforce reduction of about 60%. The company is focusing its spending on efzofitimod, with cash of $58.9 million at June 30, 2026, which it says will fund operations into late 2028; shareholders face a smaller loss but a shrinking cash balance and leadership changes.
Key points
- Q2 2026 net loss was $10.3 million, or $0.11 per share, versus $19.5 million, or $0.22 per share, in Q2 2025.
- Cash, cash equivalents, restricted cash and investments were $58.9 million at June 30, 2026, down from $80.9 million at December 31, 2025.
- CFO Jill Broadfoot steps down September 30, 2026; Brandon Yaras becomes CFO October 1, 2026. General Counsel Nancy Denyes also steps down September 30, 2026.
- Restructuring is expected to cut annualized operating expenses by about $13 million beginning in Q4 2026; the company is awaiting FDA comments on its Phase 3 protocol by the end of August 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.